Hui Liu

Hui Liu

Auto-generated profile, based on publicly available information

Hui Liu

Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
XLXufei Luo
Xufei Luo
FCFengxian Chen
Fengxian Chen
DZDi Zhu
Di Zhu
LWLing Wang
Ling Wang
ZWZijun Wang
Zijun Wang
YCYaolong Chen
Yaolong Chen
Large language models (LLMs) such as ChatGPT have become widely applied in the field of medical research. In the process of conducting systematic reviews, similar tools can be used to expedite various steps, including defining clinical questions, performing the literature search, document screening, information extraction, and language refinement, thereby conserving resources and enhancing efficiency. However, when using LLMs, attention should be paid to transparent reporting, distinguishing between genuine and false content, and avoiding academic misconduct. In this viewpoint, we highlight the potential roles of LLMs in the creation of systematic reviews and meta-analyses, elucidating their advantages, limitations, and future research directions, aiming to provide insights and guidance for authors planning systematic reviews and meta-analyses.

2 January 2023 in Talanta
Verified
Journal Article
Closed access
WZWenyan Zhu
Wenyan Zhu
GJGuangna Ji
Guangna Ji
RCRuipeng Chen
Ruipeng Chen
YXYunfeng Xiang
Yunfeng Xiang
SJShuaifeng Ji
Shuaifeng Ji
THTie Han
Tie Han

1 October 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
GLGuanyu Lu
Guanyu Lu
WYWeitao Ye
Weitao Ye
JOJiehao Ou
Jiehao Ou
XLXINYUN LI
XINYUN LI
ZTZekun Tan
Zekun Tan
HLHui Liu
Hui Liu
Coronary computed tomography angiography (CCTA) is a comprehensive, non-invasive and cost-effective imaging assessment approach, which can provide the ability to identify the characteristics and morphology of high-risk atherosclerotic plaques associated with acute coronary syndrome (ACS). The development of CCTA and latest advances in emerging technologies, such as computational fluid dynamics (CFD), have made it possible not only to identify the morphological characteristics of high-risk plaques non-invasively, but also to assess the hemodynamic parameters, the environment surrounding coronaries and so on, which may help to predict the risk of ACS. In this review, we present how CCTA was used to characterize the composition and morphology of high-risk plaques prone to ACS and the current role of CCTA, including emerging CCTA technologies, advanced analysis, and characterization techniques in prognosticating the occurrence of ACS.

17 November 2017 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
WTWen Tan
Wen Tan
ZZZhangfeng Zhong
Zhangfeng Zhong
SWShengpeng Wang
Shengpeng Wang
HLHui Liu
Hui Liu
HYHua Yu
Hua Yu
YWYitao Wang
Yitao Wang
Background: Cancer metabolic reprogramming rekindles enthusiasm for the research of metabolic regulation in cancer drug resistance. A growing number of metabolic modifiers combined with cancer drugs obtain the expected efficacy in in vitro or in vivo studies, also in clinical trial studies, indicating a good potential of enhancing efficacy and reducing resistance. Hence, a comprehensive review on the attenuations of metabolic modifiers in cancer drug resistance is necessary for rational drug design and clinical cancer drug research. Methods: Cancer drug resistance and cancer metabolic reprogramming were used as the key words to collect publications with reference value in bibliographic databases. Specifically, the focused question is the advances of metabolic modifiers on cancer resistance improvement. Figures and tables were applied to analyze the interventions in accordance with the inclusion criteria. Results: This review summarized the advances of metabolic modifiers combined with cancer drugs in in vitro, in vivo and clinical trial studies, especially for cancer resistance improvement. The relationship between metabolic regulation and cancer resistance was elaborated, and the potential metabolic modifiers were embraced. Metabolic targets were also visualized in categorization in 4 figures and expatiated in 4 tables. Three typical metabolic modifiers, namely lonidamine, 2-DG and 3-BrPA, conferring attenuation to cancer resistance were elucidated systematically. Conclusion: Metabolic regulation is an intervention with targeted perturbation in a modest manner and reflects homeostasis balance. When combined with cancer drugs, the metabolic modifiers always show exciting potential with practical significance, enhancing activity or exerting synergism.

22 July 2021 in Health Data Science
Verified
Journal Article
Open access
PDF file
SZSiya Zhao
Siya Zhao
SLShuya Lu
Shuya Lu
SWShouyuan Wu
Shouyuan Wu
ZWZijun Wang
Zijun Wang
QGQiangqiang Guo
Qiangqiang Guo
YCYaolong Chen
Yaolong Chen
Background . Hundreds of coronavirus disease 2019 (COVID-19) clinical practice guidelines (CPGs) and expert consensus statements have been developed and published since the outbreak of the epidemic. However, these CPGs are of widely variable quality. So, this review is aimed at systematically evaluating the methodological and reporting qualities of COVID-19 CPGs, exploring factors that may influence their quality, and analyzing the change of recommendations in CPGs with evidence published. Methods . We searched five electronic databases and five websites from 1 January to 31 December 2020 to retrieve all COVID-19 CPGs. The assessment of the methodological and reporting qualities of CPGs was performed using the AGREE II instrument and RIGHT checklist. Recommendations and evidence used to make recommendations in the CPGs regarding some treatments for COVID-19 (remdesivir, glucocorticoids, hydroxychloroquine/chloroquine, interferon, and lopinavir-ritonavir) were also systematically assessed. And the statistical inference was performed to identify factors associated with the quality of CPGs. Results . We included a total of 92 COVID-19 CPGs developed by 19 countries. Overall, the RIGHT checklist reporting rate of COVID-19 CPGs was 33.0%, and the AGREE II domain score was 30.4%. The overall methodological and reporting qualities of COVID-19 CPGs gradually improved during the year 2020. Factors associated with high methodological and reporting qualities included the evidence-based development process, management of conflicts of interest, and use of established rating systems to assess the quality of evidence and strength of recommendations. The recommendations of only seven (7.6%) CPGs were informed by a systematic review of evidence, and these seven CPGs have relatively high methodological and reporting qualities, in which six of them fully meet the Institute of Medicine (IOM) criteria of guidelines. Besides, a rapid advice CPG developed by the World Health Organization (WHO) of the seven CPGs got the highest overall scores in methodological (72.8%) and reporting qualities (83.8%). Many CPGs covered the same clinical questions (it refers to the clinical questions on the effectiveness of treatments of remdesivir, glucocorticoids, hydroxychloroquine/chloroquine, interferon, and lopinavir-ritonavir in COVID-19 patients) and were published by different countries or organizations. Although randomized controlled trials and systematic reviews on the effectiveness of treatments of remdesivir, glucocorticoids, hydroxychloroquine/chloroquine, interferon, and lopinavir-ritonavir for patients with COVID-19 have been published, the recommendations on those treatments still varied greatly across COVID-19 CPGs published in different countries or regions, which may suggest that the CPGs do not make sufficient use of the latest evidence. Conclusions . Both the methodological and reporting qualities of COVID-19 CPGs increased over time, but there is still room for further improvement. The lack of effective use of available evidence and management of conflicts of interest were the main reasons for the low quality of the CPGs. The use of formal rating systems for the quality of evidence and strength of recommendations may help to improve the quality of CPGs in the context of the COVID-19 pandemic. During the pandemic, we suggest developing a living guideline of which recommendations are supported by a systematic review for it can facilitate the timely translation of the latest research findings to clinical practice. We also suggest that CPG developers should register the guidelines in a registration platform at the beginning for it can reduce duplication development of guidelines on the same clinical question, increase the transparency of the development process, and promote cooperation among guideline developers all over the world. Since the International Practice Guideline Registry Platform has been created, developers could register guidelines prospectively and internationally on this platform.

10 May 2026 in Integrative Medicine Research
Verified
Journal Article
Open access
HLHui Liu
Hui Liu
KXKe Xu
Ke Xu
JZJie Zhang
Jie Zhang
SWShouyuan Wu
Shouyuan Wu
YQYishan Qin
Yishan Qin
ZBZhaoxiang Bian
Zhaoxiang Bian
Integrated Chinese-Western medicine (ICWM) is a distinctive medical system that plays an important role in healthcare and has received increasing attention in recent years. To facilitate the dissemination of evidence in ICWM, we developed an Artificial Intelligence (AI)-empowered Clinical Evidence for Integrated Chinese-Western Medicine (ACE-iMed) platform. A multidisciplinary working group was established, including individuals with professional backgrounds in evidence-based medicine methodology, Chinese medicine (CM), Western medicine (WM), and ICWM clinical practice and research, and computer science. Through multiple rounds of discussions, the working group defined the framework and methodology of the platform, and then applied the platform to summarize evidence for eight diseases. The ACE-iMed platform (website: www.aceimed.org) contains two interfaces. The first enables the developers to store and screen the literature, perform methodological quality assessments, and generate evidence summaries. The AI-empowered workflows showed good consistency and stability across multiple stages, including literature screening and assessment of risk of bias/methodological quality, and effectively support summarizing evidence for eight diseases. The second interface, intended for end users, provides synchronized access to the included literature and the generated summaries, enabling quick access to clinical question-oriented evidence resources. This study introduces an AI-empowered, clinical question-oriented ICWM evidence platform. Application across eight diseases demonstrated the platform’s feasibility and practical utility. The platform not only supports the developers in summarizing evidence but also provides end users with a potential pathway to access evidence and its summaries.